Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab onset of effect on lung function in severe eosinophilic asthma
2016-002094-36Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma and eosinophilic asthma (EA) comparing Benralizumab with Placebo (2 arms). Primary endpoint: Change from baseline to end of treatment in pre-bronchodilator FEV1. Started Sep 2016; status: completed.
02
Drugs
benralizumab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on 2016-002094-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002094-36.